3.665
price down icon4.45%   -0.155
after-market Dopo l'orario di chiusura: 3.66 -0.005 -0.14%
loading
Precedente Chiudi:
$3.82
Aprire:
$3.82
Volume 24 ore:
877.48K
Relative Volume:
0.66
Capitalizzazione di mercato:
$306.23M
Reddito:
$7.05M
Utile/perdita netta:
$-30.43M
Rapporto P/E:
-4.998
EPS:
-0.7333
Flusso di cassa netto:
$21.84M
1 W Prestazione:
-7.83%
1M Prestazione:
-15.70%
6M Prestazione:
+88.14%
1 anno Prestazione:
+148.30%
Intervallo 1D:
Value
$3.60
$3.86
Intervallo di 1 settimana:
Value
$3.60
$4.21
Portata 52W:
Value
$1.18
$4.62

Proqr Therapeutics N V Stock (PRQR) Company Profile

Name
Nome
Proqr Therapeutics N V
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
157
Name
Cinguettio
@proqr
Name
Prossima data di guadagno
2024-08-05
Name
Ultimi documenti SEC
Name
PRQR's Discussions on Twitter

Confronta PRQR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
PRQR 3.665 306.23M 7.05M -30.43M 21.84M -0.7333
VRTX 467.12 119.83B 10.63B -479.80M -1.35B 13.33
REGN 762.38 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 567.35 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.83 24.08B 3.30B -501.07M 1.03B 11.54

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-03-30 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2022-12-22 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2022-02-14 Downgrade Citigroup Buy → Neutral
2022-02-11 Downgrade Raymond James Strong Buy → Mkt Perform
2022-02-11 Downgrade Stifel Buy → Hold
2022-02-01 Iniziato Raymond James Strong Buy
2021-05-03 Iniziato Stifel Buy
2021-03-25 Reiterato Citigroup Buy
2020-11-03 Ripresa Cantor Fitzgerald Overweight
2019-03-12 Reiterato Chardan Capital Markets Buy
2018-12-19 Iniziato RBC Capital Mkts Outperform
2018-11-15 Iniziato Citigroup Buy
2018-09-19 Iniziato Evercore ISI Outperform
2017-09-26 Reiterato JMP Securities Mkt Outperform
2016-06-20 Iniziato Chardan Capital Markets Neutral
2014-10-15 Iniziato Deutsche Bank Buy
2014-10-13 Iniziato H.C. Wainwright Buy
Mostra tutto

Proqr Therapeutics N V Borsa (PRQR) Ultime notizie

pulisher
Nov 14, 2024

ProQR Therapeutics NV (MEX:PRQR) Cash Flow from Financing : MXN-38.6 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Chardan Capital Issues Pessimistic Outlook for PRQR Earnings - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

What is Chardan Capital's Forecast for PRQR FY2024 Earnings? - MarketBeat

Nov 13, 2024
pulisher
Nov 08, 2024

ProQR: Q3 Earnings Snapshot - San Francisco Chronicle

Nov 08, 2024
pulisher
Nov 08, 2024

ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00 at HC Wainwright - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

ProQR Therapeutics NV earnings beat, revenue fell short of estimates - Investing.com

Nov 07, 2024
pulisher
Nov 07, 2024

ProQR Therapeutics NV earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK

Nov 07, 2024
pulisher
Nov 07, 2024

PRQRProQR Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

ProQR Announces Third Quarter 2024 Operating and Financial Results - GlobeNewswire

Nov 07, 2024
pulisher
Nov 06, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above Fifty Day Moving AverageShould You Sell? - MarketBeat

Nov 06, 2024
pulisher
Oct 30, 2024

Raymond James Upgrades ProQR Therapeutics N.V. (PRQR) - MSN

Oct 30, 2024
pulisher
Oct 29, 2024

ProQR Therapeutics upgraded by Raymond James with a new price target - Quantisnow

Oct 29, 2024
pulisher
Oct 29, 2024

ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Strong-Buy at Raymond James - MarketBeat

Oct 29, 2024
pulisher
Oct 26, 2024

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewswire

Oct 26, 2024
pulisher
Oct 25, 2024

ProQR Announces Major Share Offering Agreement - TipRanks

Oct 25, 2024
pulisher
Oct 23, 2024

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump - Simply Wall St

Oct 23, 2024
pulisher
Oct 23, 2024

ProQR Therapeutics drops on $75 mln equity raise as Eli Lilly pitches in - XM

Oct 23, 2024
pulisher
Oct 23, 2024

Form 424B5 ProQR Therapeutics N.V. - StreetInsider.com

Oct 23, 2024
pulisher
Oct 23, 2024

ProQR launches public offering to fund RNA therapy research - Investing.com India

Oct 23, 2024
pulisher
Oct 22, 2024

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement - StockTitan

Oct 22, 2024
pulisher
Oct 22, 2024

ProQR Therapeutics announces public offering of ordinary shares - MSN

Oct 22, 2024
pulisher
Oct 22, 2024

ProQR launches public offering to fund RNA therapy research By Investing.com - Investing.com UK

Oct 22, 2024
pulisher
Oct 22, 2024

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares - GlobeNewswire

Oct 22, 2024
pulisher
Oct 20, 2024

ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance

Oct 20, 2024
pulisher
Oct 16, 2024

RNA-Editing Stocks Soar by Record on Wave Life’s Trial Data - Yahoo Finance

Oct 16, 2024
pulisher
Oct 14, 2024

Proqr Therapeutics RNA editing technology counteracts cholestatic disease - BioWorld Online

Oct 14, 2024
pulisher
Oct 07, 2024

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times

Oct 07, 2024
pulisher
Oct 07, 2024

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewswire Inc.

Oct 07, 2024
pulisher
Oct 05, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World

Oct 05, 2024
pulisher
Oct 05, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat

Oct 05, 2024
pulisher
Oct 04, 2024

Investing in ProQR Therapeutics N.V (PRQR) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News

Oct 04, 2024
pulisher
Oct 02, 2024

Best Momentum Stocks to Buy for October 2nd - Yahoo Finance

Oct 02, 2024
pulisher
Sep 30, 2024

ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 27, 2024

ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat

Sep 27, 2024
pulisher
Sep 27, 2024

ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $1.95 - Defense World

Sep 27, 2024
pulisher
Sep 26, 2024

ProQR Therapeutics N.V (PRQR) Stock: A Year of Stock Market Dynamics - The InvestChronicle

Sep 26, 2024
pulisher
Sep 26, 2024

Market Momentum: ProQR Therapeutics N.V (PRQR) Registers a 7.14 Increase, Closing at 1.80 - The Dwinnex

Sep 26, 2024
pulisher
Sep 19, 2024

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average of $1.96 - MarketBeat

Sep 19, 2024
pulisher
Sep 19, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $1.96 - Defense World

Sep 19, 2024
pulisher
Sep 10, 2024

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewswire

Sep 10, 2024
pulisher
Sep 10, 2024

ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Above 50-Day Moving Average of $1.90 - MarketBeat

Sep 10, 2024
pulisher
Sep 10, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90 - Defense World

Sep 10, 2024
pulisher
Sep 02, 2024

A look into ProQR Therapeutics N.V (PRQR)’s deeper side - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

What technical indicators reveal about PRQR stock - US Post News

Sep 02, 2024
pulisher
Sep 01, 2024

ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - Yahoo Finance UK

Sep 01, 2024
pulisher
Aug 20, 2024

ProQR Therapeutics NV (FRA:0PQ) Financial Strength : 3 (As of Jun. 2024) - GuruFocus.com

Aug 20, 2024
pulisher
Aug 18, 2024

Reviewing ProQR Therapeutics (NASDAQ:PRQR) and OptiNose (NASDAQ:OPTN) - Defense World

Aug 18, 2024
pulisher
Aug 17, 2024

ProQR Therapeutics NV (FRA:0PQ) Enterprise Value : €86.81 Mil (As of Aug. 17, 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 12, 2024

Comparing Moleculin Biotech (NASDAQ:MBRX) & ProQR Therapeutics (NASDAQ:PRQR) - Defense World

Aug 12, 2024

Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$19.00
price up icon 4.27%
$76.98
price up icon 1.23%
$39.53
price up icon 7.03%
$359.21
price down icon 0.88%
$187.76
price down icon 0.58%
$101.83
price up icon 2.00%
Capitalizzazione:     |  Volume (24 ore):